GlaxoSmithKline to Invest $250 Million in Vir Biotechnology Inc.
April 06 2020 - 8:49AM
Dow Jones News
By Matteo Castia
GlaxoSmithKline PLC said Monday that it will invest $250 million
in Vir Biotechnology Inc. as part of their new partnership to
research and develop solutions for the treatment of coronaviruses,
including the one that causes Covid-19.
The British pharma group said the collaboration will use Vir's
proprietary monoclonal antibody platform technology to accelerate
existing and identify new anti-viral antibodies that could be used
to treat coronaviruses, while GlaxoSmithKline will provide
expertise in functional genomics.
GlaxoSmithKline said that to gain access to Vir's technology, it
will buy Vir's shares at $37.73, a 10% premium to the closing share
price on Friday.
GlaxoSmithKline shares at 1315 GMT were up 3.2 pence, or 0.2%,
at 1,492.6 pence.
Write to Matteo Castia at matteo.castia@dowjones.com
(END) Dow Jones Newswires
April 06, 2020 08:34 ET (12:34 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
